Skip to main content

Treasury Department Issues Updated Guidance On Hemp Banking Rules

Oregon activists behind an initiative to legalize psilocybin mushrooms for therapeutic purposes announced on Monday that they have secured more than enough valid signatures to qualify for the November ballot.

While the secretary of state’s office hasn’t yet verified all of the signatures, the Yes On IP34 campaign said it has independently determined that they’ve gathered enough to make the cut ahead of a July 2 submission deadline.

Last week, the state verified that the team had turned in 106,908 of the 112,020 needed signatures to make the ballot.

At a virtual press conference, the campaign revealed it has collected a new total of 164,782 signatures, and will submit the additional petitions on Monday, giving them “great confidence that Oregon’s psilocybin therapy initiative will qualify for the statewide ballot.”

“Now, we’ll get the official word from the secretary of state sometime next month, but our submission of signatures today will put us comfortably above those requirements,” Tom Eckert, chief petitioner, said.

The campaign’s prior petition submissions were validated by the state at an 80.2% approval rate. Of the new 31,209 signatures filed, only 5,112 (or 16.4 percent) must be deemed valid for the measure to officially qualify for ballot access.

Via Yes on IP 34.

“This initiative is about giving Oregonians safe, legal, regulated access to psilocybin-assisted therapy in licensed settings, with trained and competent facilitators,” he said. “That’s what the science supports. That’s our approach in Oregon. And that’s why we believe Oregonians deserve access.”

If it ultimately qualifies and voters approve it, Oregon would become the first jurisdiction in the U.S. to implement a therapeutic legalization model for so-called magic mushrooms. There wouldn’t be any specific conditions that make people eligible for the therapy.

This development is one of the latest examples of the success of the psychedelics reform movement after Denver became the first place in the U.S. to deprioritize enforcement of laws against psilocybin last year.

That was followed by a unanimous Oakland City Council vote in favor of a measure to make a wide range of entheogenic substances among the city’s lowest law enforcement priorities. The Santa Cruz City Council followed suit, and activists in more than 100 cities are now exploring ways to enact the policy change.

Washington, D.C. advocates are also in the final stages of collecting signatures for a psychedelics decriminalization initiative after being temporarily set back by the coronavirus pandemic.

Here’s a status update on other drug policy reform campaigns across the country: 

Also in Oregon, a campaign working to put a measure on the ballot that would decriminalize currently illicit drugs and make investments in substance misuse treatment submitted more than 147,000 signatures last month, and it’s continued the gathering process as the deadline approaches on Thursday.

Washington State activists had planned to pursue a similar measure through the ballot, but citing concerns about the COVID-19 outbreak, they announced last week that they will be targeting the legislature instead.

Idaho activists behind a medical marijuana legalization initiative could get a second wind after a federal judge said last week that the state must make accommodations for a separate ballot campaign due to signature gathering complications due to the coronavirus pandemic.

Montana activists recently turned in more than 130,000 signatures to qualify a pair of legalization initiatives for the November ballot.

Nebraska activists are approaching a deadline next month to submit signatures for a proposed medical cannabis initiative.

In Arizona, the organizers of a legalization effort asked the state Supreme Court to instruct the secretary of state to allow people to sign cannabis petitions digitally using an existing electronic system that is currently reserved for individual candidates seeking public office. That request was denied, but advocates are still optimistic about the chances of making the ballot.

Prior to the COVID-19 outbreak and stay-at-home mandates, measures to legalize marijuana for medical and recreational purposes qualified for South Dakota’s November ballot.

The New Jersey legislature approved putting a cannabis legalization referendum before voters as well.

And in Mississippi, activists gathered enough signatures to qualify a medical cannabis legalization initiative for the ballot—though lawmakers also approved a competing (and from advocates’ standpoint, less desirable) medical marijuana proposal that will appear alongside the campaign-backed initiative.

A campaign to legalize cannabis in Missouri officially gave up its effort for 2020 due to signature collection being virtually impossible in the face of social distancing measures.

North Dakota activists said they plan to continue campaign activities for a marijuana legalization initiative, but it’s more likely that they will seek qualification for the 2022 ballot.

Bipartisan Senators File Marijuana And CBD Research Amendment To Defense Spending Bill

Photo courtesy of Dick Culbert.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Comments

Post a Comment

Popular posts from this blog

New York City Adds More Exceptions To Pre-Employment Marijuana Testing Ban

An ambitious campaign to decriminalize psychedelics in Washington, D.C., is one step closer to placing their measure on the November ballot with the formal submission of tens of thousands of voter signatures. Organizers have been scrambling for weeks to collect enough signatures from D.C. voters by Monday’s deadline amid historically difficult circumstances: a global pandemic, months of stay-at-home orders and protests over racism and police violence that filled the streets of the nation’s capital. But with the help of innovative signature-gathering techniques and allies flown in from across the country, advocates said they had successfully submitted upwards of 35,000 signatures—more than enough to qualify the initiative. If approved by voters, Initiative 81 would make enforcement of laws against plant- and fungus-based psychedelics among the “lowest law enforcement priorities” for the Metropolitan Police Department. It would not, however, legalize or reduce penalties for the subs
Post a Comment
Read more

Charlotte Figi The Girl Who Inspired A CBD Movement Has Died At Age 13

Charlotte had recently been hospitalized due to pneumonia, breathing problems and seizures. She was treated as a likely case of Covid-19, her mother, Paige Figi, said Wednesday, although she tested negative for the virus. “Charlotte is no longer suffering. She is seizure-free forever,” a family friend wrote on Paige Figi’s Facebook page, announcing Charlotte’s death. “Thank you so much for all of your love.” Charlotte became a symbol of the possibilities of CBD after CNN Chief Medical Correspondent Dr. Sanjay Gupta told her story in the documentary “Weed.” In the film, Charlotte was shown to be a playful child who was overcome by horrific seizures, which were quelled with Charlotte’s Web, a marijuana strain named in her honor. Charlotte had Dravet syndrome, a rare form of epilepsy which was not controlled by medication. The Stanley brothers, marijuana growers in Colorado, were crossbreeding a strain of marijuana high in CBD and low in THC, its psychoactive ingredient. After Charlo
Post a Comment
Read more

Virginia CBD Program Criticized As Multistate Medical Cannabis Operators Gain Edge

Seven companies are challenging a CBD licensing process in Virginia that resulted in multistate medical marijuana operators getting a majority of available licenses. The appeals called the process “wildly prejudicial.” Out of 51 applicants for five vertically integrated CBD and THC-A licenses, multistate operators received three, a situation that spurred the appeals, The Virginian-Pilot reported. Applicants filing the appeals complained the closed-meeting review process lacked fairness and transparency. One consultant to an applicant said the selections felt “predetermined.” The Virginia Board of Pharmacy reportedly sent information to the applicants in December explaining its selections, but some applicants weren’t satisfied. A board spokeswoman wrote in an email to the Pilot that the board “does not comment on pending litigation.” The five winning applicants , called “pharmaceutical processors,” have a year from winning the licenses to become operational. The multistate
Post a Comment
Read more